Recent Quotes
My Watchlist
Indicators
Local Stocks
NewsOK Local Stocks
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Savara Inc (NQ: SVRA )

2.980 -0.210 (-6.58%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 15, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,586,572
Open 3.210
Bid (Size) 2.860 (5)
Ask (Size) 3.300 (1)
Prev. Close 3.190
Today's Range 2.830 - 3.225
52wk Range 2.830 - 5.700
Shares Outstanding 114,066,080
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Savara Announces Participation in Upcoming Healthcare Conferences
From Savara Inc.
Via Business Wire
Savara Reports Third Quarter 2024 Financial Results and Provides Business Update
From Savara Inc.
Via Business Wire

Performance

YTD
-31.81%
-31.81%
1 Month
-18.36%
-18.36%
3 Month
-33.92%
-33.92%
6 Month
-36.86%
-36.86%
1 Year
-18.58%
-18.58%

More News

Read More
Savara to Present at the Guggenheim Inaugural Healthcare Innovation Conference
From Savara Inc.
Via Business Wire
SVRA Stock Earnings: Savara Misses EPS for Q2 2024
Via InvestorPlace
Savara Announces the Rare Lung Disease, Autoimmune Pulmonary Alveolar Proteinosis (aPAP), is Highlighted on a New Episode of “The Balancing Act®” Airing on Lifetime® TV
From Savara Inc.
Via Business Wire
Savara Announces New Employment Inducement Grant
From Savara Inc.
Via Business Wire
Savara Announces Patient Journey Map for People Living with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Accepted for Poster Presentation at the CHEST 2024 Annual Meeting
From Savara Inc.
Via Business Wire
Savara Announces New Employment Inducement Grant
From Savara Inc.
Via Business Wire
Savara Announces Expanded Access Program (EAP) for Molgramostim Inhalation Solution (Molgramostim) for Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
From Savara Inc.
Via Business Wire
Savara Appoints Braden Parker as Chief Commercial Officer, Effective Immediately
From Savara Inc.
Via Business Wire
Savara to Host Analyst and Investor Webinar on September 30, 2024
From Savara Inc.
Via Business Wire
Why Summit Therapeutics Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Savara Announces New Data from Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Were Presented at the European Respiratory Society (ERS) Congress 2024
From Savara Inc.
Via Business Wire
Savara Announces New Employment Inducement Grant
From Savara Inc.
Via Business Wire
Savara to Present at the H.C. Wainwright 26th Annual Global Investment Conference
From Savara Inc.
Via Business Wire
Savara Announces New Employment Inducement Grant
From Savara Inc.
Via Business Wire
Savara to Present New Data from Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the European Respiratory Society (ERS) Congress 2024
From Savara Inc.
Via Business Wire
Savara Reports Second Quarter 2024 Financial Results and Provides Business Update
From Savara Inc.
Via Business Wire
Savara Announces Pricing of $100.0 Million Underwritten Offering of Common Stock
From Savara Inc.
Via Business Wire
Why Is Respiratory Disease-Focused Savara Stock Trading Higher On Wednesday?
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Via InvestorPlace
Savara Announces Molgramostim Nebulizer Solution (Molgramostim) Achieved Statistical Significance for Primary Endpoint and Multiple Secondary Endpoints in IMPALA-2, a Pivotal Phase 3 Clinical Trial in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
From Savara Inc.
Via Business Wire
Savara to Host Investor Call to Discuss Top Line Results From Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
From Savara Inc.
Via Business Wire
3 Penny Stocks Poised for Major Upside Over the Next 5 Years
Via InvestorPlace
3 Penny Stocks That Can Deliver Over 5,000% Upside by 2025: June Edition
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.